Strategic collaboration Molecure has actively pursued partnerships, including an exclusive licensing agreement with Ocean Biomedical in 2024, presenting a potential channel for co-development, funding, and access to new markets or resources.

Clinical expansion With OATD-01 in Phase II for sarcoidosis and OATD-02 in early clinical trials, there is ongoing clinical activity and a need for related services such as contract research, imaging, biomarker analytics, and regulatory support to sustain trials.

Investors and growth Recent growth funding and FDA-cleared pulmonary sarcoidosis trial signal investor confidence and potential demand for CRO and consulting services to support rapid program execution and data compilation for milestones.

Geographic footprint Headquartered in Warsaw with additional labs in Łódź, Molecure may benefit from regional CRO partnerships, local regulatory navigation, and translational research alliances within Poland and adjacent EU markets.

Public market visibility Being listed on the Warsaw Stock Exchange and active press coverage provides opportunities for investor relations, patient recruitment partnerships, and corporate storytelling services to strengthen market positioning and stakeholder engagement.